Genetic Testing in Metastatic Colorectal Cancer: A Crucial Step Towards Targeted Treatments

Image credits: DelveInsight

Genetic testing is a laboratory method used to detect changes in genes, gene expression or chromosomes in a person's cells or tissues. In the context of metastatic colorectal cancer, genetic testing may identify inherited gene changes that indicate an increased risk of developing the disease or passing it to a family member. Additionally, genetic testing can analyze tumor tissue for genetic changes in cancer cells that develop during a person’s lifetime, which is known as somatic testing. This type of testing helps assess the cancer, guide treatment or monitor treatment response. Recent advances in precision medicine have resulted in new treatments targeting genetic mutations, highlighting the importance of genetic testing in metastatic colorectal cancer.

The FDA has approved a combination therapy for adults with metastatic colorectal cancer who have previously received chemotherapy based on fluoropyrimidine, oxaliplatin and irinotecan. This approval was based on findings from the phase 3 CodeBreaK 300 trial, which supported the use of a combination of Lumakras (sotorasib) and Vectibix (panitumumab) for patients with KRAS G12C-mutated metastatic colorectal cancer. According to Dr. Marwan G. Fakih, lead investigator and professor of medical oncology at City of Hope in Duarte, California, every single patient with metastatic colorectal cancer should have upfront next-generation sequencing of their treatment, meaning full profiling of the genetic alterations of their cancer. This approach enables healthcare providers to identify the most effective treatment options, including targeted therapies that address specific mutations.

In addition to metastatic colorectal cancer, genetic testing also plays a crucial role in other types of cancer, such as metastatic castration-resistant prostate cancer (mCRPC). The mCRPC market is expected to witness significant growth during the forecast period, driven by the extensive market penetration of approved therapies and the entry of new emerging therapies. Several companies, including Amgen, Xencor, and Orion, are evaluating new treatments for mCRPC, including xaluritamig, a STEAP1 x CD3 XmAb 2+1 bispecific antibody, and opevesostat, an oral, non-steroidal, selective CYP11A1 inhibitor. The emergence of new therapies, such as PARP inhibitors and immunotherapies, is expected to transform the mCRPC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

The importance of genetic testing in cancer treatment cannot be overstated. By identifying specific genetic mutations, healthcare providers can develop personalized treatment plans that target the underlying causes of the disease. This approach has the potential to improve patient outcomes, reduce treatment costs, and enhance the overall quality of life for individuals with cancer. As the field of precision medicine continues to evolve, it is likely that genetic testing will play an increasingly important role in the diagnosis and treatment of various types of cancer, including metastatic colorectal cancer and mCRPC. The use of next-generation sequencing and other advanced technologies will enable healthcare providers to analyze complex genetic data, identify new therapeutic targets, and develop more effective treatments for cancer patients.

In conclusion, genetic testing is a critical component of cancer treatment, enabling healthcare providers to develop personalized treatment plans that target specific genetic mutations. The recent FDA approvals and the emergence of new therapies, such as targeted therapies and immunotherapies, highlight the importance of genetic testing in metastatic colorectal cancer and other types of cancer. As the field of precision medicine continues to evolve, it is likely that genetic testing will play an increasingly important role in the diagnosis and treatment of cancer, improving patient outcomes and enhancing the overall quality of life for individuals with cancer.